Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2014

View Archived Issues

Investigators identify biomarker for patients with Sjogren's syndrome

Clinical trial data presented for benralizumab as a treatment for asthma, COPD

Mouse papillomavirus model developed for testing antiviral responses

Novel anticancer agents divulged by Suzhou NeuPharma

Fixed-dose combinations of tiotropium and olodaterol compared to current monotherapies

Spanish scientists patent novel Dnmt1 inhibitors for cancer

GlaxoSmithKline patent describes novel DGAT1 inhibitors for obesity

Merck & Co. discloses novel prodrugs of SYK inhibitors

U.S. researchers divulge new coagulation factor XIa modulators

Bayer to codevelop Orion's ODM-201 for prostate cancer

Horizon Discovery acquires CombinatoRx service business and assets from Zalicus

ReGenX Biosciences and Voyager Therapeutics form NAV vector license agreement

Ipca and Oncobiologics form biosimilars partnership

TechnoVax receives NIH grant to develop RSV vaccine

Extended funding supports SomaLogic's development of TB diagnostic

Myriad Genetics and cancer researchers establish PROMPT genetic registry

Theravance and Theravance Biopharma separate to form two independent companies

First-in-human phase I study of RO-5520985 for advanced solid tumors

Prosensa provides regulatory update for drisapersen for DMD

Teva Pharmaceutical to acquire Labrys Biologics

Aastrom Biosciences' acquisition of Sanofi's CTRM unit complete

Asana BioSciences acquires Endo's early-stage drug discovery portfolio

Merck KGaA collaborates with Sysmex Inostics on blood-based RAS biomarker test

ASP-2215, a dual receptor tyrosine kinase inhibitor for the treatment of leukemia

EMA grants accelerated assessment to nintedanib MAA for IPF

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...